For research use only. Not for therapeutic Use.
CDK9 inhibitor HH1 is a potent and selectively CDK9 inhibitor. CDK9 inhibitor HH1 inhibits the transcription of CDK. CDK9 inhibitor HH1 can be used in research of cancer[1].
Catalog Number | I041105 |
CAS Number | 204188-41-0 |
Synonyms | [4-amino-2-(propan-2-ylamino)-1,3-thiazol-5-yl]-phenylmethanone |
Molecular Formula | C13H15N3OS |
Purity | ≥95% |
InChI | InChI=1S/C13H15N3OS/c1-8(2)15-13-16-12(14)11(18-13)10(17)9-6-4-3-5-7-9/h3-8H,14H2,1-2H3,(H,15,16) |
InChIKey | WHJIFFVMTRXENN-UHFFFAOYSA-N |
SMILES | CC(C)NC1=NC(=C(S1)C(=O)C2=CC=CC=C2)N |
Reference | [1]. Pandey S, et, al. Selective CDK9 Inhibition by Natural Compound Toyocamycin in Cancer Cells. Cancers (Basel). 2022 Jul 8;14(14):3340. |